PIN and ASAP are changes in the cells in the prostate, which can only be seen under a microscope. PIN stands for prostatic intraepithelial neoplasia. ASAP stands for atypical small acinar proliferation.

If you've been diagnosed with PIN, it's probably high grade PIN. There is also low grade PIN, but there's no evidence that this can cause problems in a man's lifetime. You can check with your doctor if you're not sure. When we say PIN, we mean high grade PIN.

PIN is not the same as prostate cancer.

Updated June 2016

To be reviewed June 2018



What is PIN?

PIN is not prostate cancer.


PIN stands for prostatic intraepithelial neoplasia. It's the name for certain kinds of changes to cells in the prostate. These changes can only be seen under a microscope.

We don't know what causes PIN, but we do know that the chance of finding it increases as you get older.  

Although PIN is not prostate cancer, many men with prostate cancer do have some PIN as well. Not all men with PIN get prostate cancer.

Back to contents

What is ASAP?

ASAP stands for atypical small acinar proliferation. It means there are unusual cells in your prostate but it's not clear what they are or if they are cancerous.  

ASAP can be a group of cells that could be cancer cells but that are still too small to see clearly under the microscope. This means they can't be diagnosed as cancer cells. Or ASAP might be other unusual cell changes that won't become cancer.  Because it's uncertain, you will usually need to have more tests if you have ASAP.

It's possible to have both ASAP and PIN in your prostate.

Back to contents

Am I more likely to get prostate cancer?

You may be more likely to develop prostate cancer if you have PIN or ASAP.

If you've been diagnosed with PIN or ASAP and are worried about prostate cancer, speak to your doctor or nurse.

Read more about your risk of getting prostate cancer. Or you could speak to one of our Specialist Nurses.

Back to contents

How are PIN and ASAP found?

PIN and ASAP can only be found by looking at prostate tissue under a microscope. This might happen if:

Back to contents

What are the symptoms?

PIN and ASAP don't cause any symptoms on their own. But they're usually diagnosed when a man has tests or treatment for another prostate problem, which often does have symptoms. For example, if you have an enlarged prostate as well as PIN, you might have problems urinating (peeing) that are caused by the enlarged prostate, not the PIN.

If you do have any symptoms such as problems urinating, speak to your doctor. They can do more tests to find out what's causing them, and suggests treatments that may help.

Back to contents

Will I need treatment?

You won't need any treatment for PIN or ASAP, but you might need regular check-ups to check for any changes that might suggest that cancer is growing.

You may have:

You might also have an MRI scan to check there's no cancer in parts of the prostate that weren't looked at in your biopsy.

The tests you have will depend on your own situation. Talk to your doctor or nurse if you have any questions . You can also speak to our Specialist Nurses.

If you are diagnosed with cancer, it is more likely to be an early stage because you'll have had these regular check-ups. This means it can be carefully monitored or treated if necessary.

If you do get prostate cancer, you won't continue to have regular check-ups for PIN or ASAP.

Back to contents

Questions to ask your doctor or nurse

  • Have I got high grade PIN or ASAP?
  • How much high grade PIN or ASAP do I have?
  • Do I need further tests to find out more?
  • What is my risk of getting prostate cancer?
  • Can I do anything to reduce my risk of prostate cancer?
  • How often will I need to have check-ups?
  • What will my check-ups involve?
  • Will I need to have another biopsy?
  • Will I need any other tests?

Back to contents


Updated April 2016 | Due for review April 2018

  • Full list of references used to produce this page  

    • Aganovic, D., Prcic, A., Kulovac, B. & Hadziosmanovic, O. Prostate cancer detection rate and the importance of premalignant lesion in rebiopsy. Med Arh 65, 109–12 (2011).
    • Albertsen, P. C. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncologica 50, 120–126 (2011).
    • Alsikafi, N. F., Brendler, C. B., Gerber, G. S. & Yang, X. J. High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 57, 296–300 (2001).
    • Ben-Shlomo, Y. et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur. Urol. 53, 99–105 (2008).
    • Bigler, S. A., Pound, C. R. & Zhou, X. A Retrospective Study on Pathologic Features and Racial Disparities in Prostate Cancer. Prostate Cancer 2011, 1–7 (2011).
    • Bostwick, D. G. & Cheng, L. Precursors of prostate cancer: Precursors of prostate cancer. Histopathology 60, 4–27 (2012).
    • Bostwick, D. G. & Meiers, I. Atypical small acinar proliferation in the prostate: clinical significance in 2006. Archives of pathology & laboratory medicine 130, 952–957 (2006).
    • Capodice, J. et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 7, 43–51 (2009).
    • Carver, B. S. et al. RACE IS NOT A PREDICTOR OF PROSTATE CANCER DETECTION ON REPEAT PROSTATE BIOPSY. The Journal of Urology 172, 1853–1855 (2004).
    • Clouston, D. & Bolton, D. In situ and intraductal epithelial proliferations of prostate: Definitions and treatment implications Part 1: Prostatic intraepithelial neoplasia. BJU international 109, 22–26 (2012).
    • Clouston, D. & Bolton, D. In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 2: intraductal carcinoma and ductal adenocarcinoma of prostate. BJU Int. 110 Suppl 4, 22–24 (2012).
    • De Nunzio, C. et al. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J. Urol. 181, 1069–1074; discussion 1074–1075 (2009).
    • Dickinson, S. I. Premalignant and malignant prostate lesions: pathologic review. Cancer Control 17, 214–222 (2010).
    • Dorin, R. P., Wiener, S., Harris, C. D. & Wagner, J. R. Prostate atypia: Does repeat biopsy detect clinically significant prostate cancer?: Repeat Biopsy Following Prostate Atypia. The Prostate 75, 673–678 (2015).
    • Heidenreich, A. et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. European Urology 59, 61–71 (2011).
    • Jones, A. L. & Chinegwundoh, F. Update on prostate cancer in black men within the UK. Ecancermedicalscience 8, 455 (2014).
    • Klein, E. A. & Thompson, I. M. Chemoprevention of prostate cancer: an updated view. World Journal of Urology 30, 189–194 (2012).
    • Koca, O., Çalışkan, S., Öztürk, M. İ., Güneş, M. & Karaman, M. I. Significance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy. Korean Journal of Urology 52, 736 (2011).
    • Laurila, M. et al. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. European Journal of Cancer 46, 3068–3072 (2010).
    • Lee, K. Y., Choi, Y., Lee, K., Yun, S. & Choe, G. Atypical small acinar proliferation of prostate: Follow-up study of 114 patients: 114 cases of prostatic ASAP. Basic and Applied Pathology 4, 116–119 (2011).
    • Lee, M. C. et al. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J. Urol. 184, 1958–1962 (2010).
    • Leone, L. et al. Biopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy. Archivio Italiano di Urologia e Andrologia 86, 332 (2014).
    • Lloyd, T. et al. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Medicine 13, (2015).
    • Maccagnano, C. et al. Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. Urologia Internationalis 89, 126–135 (2012).
    • Merrimen, J. L. et al. A Model to Predict Prostate Cancer After Atypical Findings in Initial Prostate Needle Biopsy. The Journal of Urology 185, 1240–1245 (2011).
    • Merrimen, J. L. et al. Multifocal High Grade Prostatic Intraepithelial Neoplasia is a Significant Risk Factor for Prostatic Adenocarcinoma. The Journal of Urology 182, 485–490 (2009).
    • Merrimen, J. L. O., Evans, A. J. & Srigley, J. R. Preneoplasia in the prostate gland with emphasis on high grade prostatic intraepithelial neoplasia: Pathology 45, 251–263 (2013).
    • Montironi, R. et al. Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as ‘atypical small acinar proliferation suspicious for but not diagnostic of malignancy’). Eur. Urol. 50, 666–674 (2006).
    • Montironi, R. et al. Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies. European Urology 50, 666–674 (2006).
    • Montironi, R., Mazzucchelli, R., Lopez-Beltran, A., Scarpelli, M. & Cheng, L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU International 108, 1394–1401 (2011).
    • Mottet N et al. Guidelines on prostate cancer. (2015).
    • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. (2014).
    • NHS Cancer Screening Programmes. Undertaking a transrectal ultrasound guided biopsy of the prostate. PCRMP Guide No 1. (2006).
    • Novara, G. et al. Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate. BJU International 105, 1242–1246 (2010).
    • Pal, R. P., Elmussareh, M., Chanawani, M. & Khan, M. A. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies: TRANSPERINEAL PROSTATE BIOPSY TECHNIQUE. BJU International 109, 367–371 (2012).
    • Ploussard, G. et al. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World journal of urology 27, 587–592 (2009).
    • Roehrborn, C. G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 101 Suppl 3, 17–21 (2008).
    • Sakr, W. et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30, 138–44 (1996).
    • Sakr, W. et al. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 191, 838–41 (1995).
    • Selvadurai, E. D. et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur. Urol. 64, 981–987 (2013).
    • Thompson, I. M. et al. Finasteride Decreases the Risk of Prostatic Intraepithelial Neoplasia. The Journal of Urology 178, 107–110 (2007).
    • Zanardi, S. et al. Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies. Cancer Prevention Research 2, 377–384 (2009).
    • Zynger, D. L. & Yang, X. High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer. International journal of clinical and experimental pathology 2, 327 (2009).